{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,12]],"date-time":"2026-05-12T19:19:10Z","timestamp":1778613550442,"version":"3.51.4"},"reference-count":35,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T00:00:00Z","timestamp":1763337600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003453","name":"Natural Science Foundation of Guangdong Province","doi-asserted-by":"publisher","award":["2023A1515010321"],"award-info":[{"award-number":["2023A1515010321"]}],"id":[{"id":"10.13039\/501100003453","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Ganzhou City science and technology plan project","award":["2022--RC1341"],"award-info":[{"award-number":["2022--RC1341"]}]},{"DOI":"10.13039\/501100004479","name":"Natural Science Foundation of Jiangxi Province","doi-asserted-by":"publisher","award":["20224ACB206007"],"award-info":[{"award-number":["20224ACB206007"]}],"id":[{"id":"10.13039\/501100004479","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Jiangxi Gan Pok Talent Support Program - Training program for academic and technical leaders in major disciplines","award":["20232BCJ22018"],"award-info":[{"award-number":["20232BCJ22018"]}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82103276"],"award-info":[{"award-number":["82103276"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"the Natural Science Foundation of Guangdong Province","award":["2024A1515010331"],"award-info":[{"award-number":["2024A1515010331"]}]},{"name":"the Outstanding Youths Development Scheme of Nanfang Hospital, Southern Medical University","award":["2021J005"],"award-info":[{"award-number":["2021J005"]}]},{"name":"Science and Technology Planning Project of Guangzhou City, Guangdong, China","award":["202201020582"],"award-info":[{"award-number":["202201020582"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Biomed"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>Castration-resistant prostate cancer (CRPC) poses a significant clinical challenge, characterized by limited therapeutic options and unfavorable prognosis, particularly among elderly men. Reactivation of androgen receptor (AR) signaling remains the principal driver of CRPC cell survival and tumor progression even under castrated levels of serum androgen. Lysine methyltransferase 2D (KMT2D) has been established as a key oncogenic driver in prostate cancer, promoting tumor progression via multiple pathways. However, its functional interaction with the AR signaling axis in the context of CRPC remains incompletely understood. In this study, we demonstrate that KMT2D substantially upregulates AR protein levels, thereby reactivating AR signaling under castration conditions. Mechanistically, KMT2D employs its histone methyltransferase function to transcriptionally enhance the expression of G3BP stress granule assembly factor 1 (G3BP1). Upregulated G3BP1 subsequently suppresses the activity of the E3 ubiquitin ligase Speckle Type BTB\/POZ protein (SPOP), leading to diminished AR ubiquitination and impaired proteasomal degradation. Furthermore, we explored a novel combination therapy involving the histone methyltransferase inhibitor MI-503 and enzalutamide in AR-positive and AR splice variant-positive cell lines. Our results confirmed the synergistic therapeutic effects of this combination, which can continue to inhibit the AR signaling pathway during the CRPC stage, thereby delaying disease progression. Taken together, our findings elucidate a critical KMT2D\/G3BP1\/SPOP\/AR regulatory axis in prostate cancer progression and propose that targeted inhibition of histone methylation in combination with anti-androgen therapy represents a promising strategy for the management of advanced prostate cancer.<\/jats:p>","DOI":"10.1186\/s43556-025-00354-8","type":"journal-article","created":{"date-parts":[[2025,11,17]],"date-time":"2025-11-17T10:04:17Z","timestamp":1763373857000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Histone methyltransferase KMT2D targets the SPOP-G3BP1 axis to enhance AR stability and drive castration-resistant prostate cancer progression"],"prefix":"10.1186","volume":"6","author":[{"given":"Haoran","family":"Wen","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Maierhaba","family":"Maheremu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kaidi","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liuru","family":"Bao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mayao","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yifan","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuanpeng","family":"Liao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Manli","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chenwei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shidong","family":"Lv","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaofu","family":"Qiu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5925-6922","authenticated-orcid":false,"given":"Qiang","family":"Wei","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,17]]},"reference":[{"issue":"1","key":"354_CR1","doi-asserted-by":"publisher","first-page":"12","DOI":"10.3322\/caac.21820","volume":"74","author":"RL Siegel","year":"2024","unstructured":"Siegel RL, Giaquinto AN, Jemal A. Cancer statistics, 2024. CA Cancer J Clin. 2024;74(1):12\u201349. https:\/\/doi.org\/10.3322\/caac.21820.","journal-title":"CA Cancer J Clin"},{"key":"354_CR2","doi-asserted-by":"publisher","first-page":"211","DOI":"10.2147\/RRU.S388265","volume":"17","author":"A Quistini","year":"2025","unstructured":"Quistini A, Chierigo F, Fallara G, Depalma M, Tozzi M, Maggi M, et al. Androgen receptor signalling in prostate cancer: mechanisms of resistance to endocrine therapies. Res Rep Urol. 2025;17:211\u201323. https:\/\/doi.org\/10.2147\/RRU.S388265.","journal-title":"Res Rep Urol"},{"issue":"3","key":"354_CR3","doi-asserted-by":"publisher","first-page":"219","DOI":"10.1111\/iju.15628","volume":"32","author":"D Obinata","year":"2025","unstructured":"Obinata D, Yamada Y, Sumiyoshi T, Tanegashima T, Watanabe R, Kobayashi H, et al. Recent advances in basic research on prostate cancer: where we are heading? Int J Urol. 2025;32(3):219\u201328. https:\/\/doi.org\/10.1111\/iju.15628.","journal-title":"Int J Urol"},{"issue":"21","key":"354_CR4","doi-asserted-by":"publisher","first-page":"4504","DOI":"10.1158\/1078-0432.CCR-22-3736","volume":"29","author":"N Menssouri","year":"2023","unstructured":"Menssouri N, Poiraudeau L, Helissey C, Bigot L, Sabio J, Ibrahim T, et al. Genomic profiling of metastatic castration-resistant prostate cancer samples resistant to androgen receptor pathway inhibitors. Clin Cancer Res. 2023;29(21):4504\u201317. https:\/\/doi.org\/10.1158\/1078-0432.CCR-22-3736.","journal-title":"Clin Cancer Res"},{"key":"354_CR5","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1016\/j.semcancer.2021.11.001","volume":"82","author":"DG Tang","year":"2022","unstructured":"Tang DG. Understanding and targeting prostate cancer cell heterogeneity and plasticity. Semin Cancer Biol. 2022;82:68\u201393. https:\/\/doi.org\/10.1016\/j.semcancer.2021.11.001.","journal-title":"Semin Cancer Biol"},{"issue":"4","key":"354_CR6","doi-asserted-by":"publisher","first-page":"209","DOI":"10.1038\/s41585-021-00438-4","volume":"18","author":"KT Schmidt","year":"2021","unstructured":"Schmidt KT, Huitema ADR, Chau CH, Figg WD. Resistance to second-generation androgen receptor antagonists in prostate cancer. Nat Rev Urol. 2021;18(4):209\u201326. https:\/\/doi.org\/10.1038\/s41585-021-00438-4.","journal-title":"Nat Rev Urol"},{"key":"354_CR7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.canlet.2021.06.006","volume":"518","author":"A Jamroze","year":"2021","unstructured":"Jamroze A, Chatta G, Tang DG. Androgen receptor (AR) heterogeneity in prostate cancer and therapy resistance. Cancer Lett. 2021;518:1\u20139. https:\/\/doi.org\/10.1016\/j.canlet.2021.06.006.","journal-title":"Cancer Lett"},{"issue":"12","key":"354_CR8","doi-asserted-by":"publisher","first-page":"706","DOI":"10.1038\/s41585-023-00795-2","volume":"20","author":"N Pernigoni","year":"2023","unstructured":"Pernigoni N, Guo C, Gallagher L, Yuan W, Colucci M, Troiani M, et al. The potential role of the microbiota in prostate cancer pathogenesis and treatment. Nat Rev Urol. 2023;20(12):706\u201318. https:\/\/doi.org\/10.1038\/s41585-023-00795-2.","journal-title":"Nat Rev Urol"},{"key":"354_CR9","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2021.728054","volume":"12","author":"F Naseer","year":"2021","unstructured":"Naseer F, Ahmad T, Kousar K, Anjum S. Advanced therapeutic options for treatment of metastatic castration resistant prostatic adenocarcinoma. Front Pharmacol. 2021;12:728054. https:\/\/doi.org\/10.3389\/fphar.2021.728054.","journal-title":"Front Pharmacol"},{"issue":"2","key":"354_CR10","doi-asserted-by":"publisher","first-page":"191","DOI":"10.1080\/14737140.2022.2020651","volume":"22","author":"MC Nigro","year":"2022","unstructured":"Nigro MC, Mollica V, Marchetti A, Cheng M, Rosellini M, Montironi R, et al. Current androgen receptor antagonists under investigation for resistant prostate cancer. Expert Rev Anticancer Ther. 2022;22(2):191\u2013202. https:\/\/doi.org\/10.1080\/14737140.2022.2020651.","journal-title":"Expert Rev Anticancer Ther"},{"key":"354_CR11","doi-asserted-by":"publisher","unstructured":"Lv S, Song Q, Chen G, Cheng E, Chen W, Cole R, et al. Regulation and targeting of androgen receptor nuclear localization in castration-resistant prostate cancer. J Clin Invest. 2021;131(4). https:\/\/doi.org\/10.1172\/JCI141335.","DOI":"10.1172\/JCI141335"},{"key":"354_CR12","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2023.104500","volume":"90","author":"CL Hung","year":"2023","unstructured":"Hung CL, Liu HH, Fu CW, Yeh HH, Hu TL, Kuo ZK, et al. Targeting androgen receptor and the variants by an orally bioavailable proteolysis targeting chimeras compound in castration resistant prostate cancer. EBioMedicine. 2023;90:104500. https:\/\/doi.org\/10.1016\/j.ebiom.2023.104500.","journal-title":"EBioMedicine"},{"issue":"13","key":"354_CR13","doi-asserted-by":"publisher","first-page":"1296","DOI":"10.18632\/oncotarget.27988","volume":"12","author":"SS Dhar","year":"2021","unstructured":"Dhar SS, Lee MG. Cancer-epigenetic function of the histone methyltransferase KMT2D and therapeutic opportunities for the treatment of KMT2D-deficient tumors. Oncotarget. 2021;12(13):1296\u2013308. https:\/\/doi.org\/10.18632\/oncotarget.27988.","journal-title":"Oncotarget"},{"key":"354_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.lfs.2025.123523","volume":"369","author":"K Wang","year":"2025","unstructured":"Wang K, Zhan F, Yang X, Jiao M, Wang P, Zhang H, et al. KMT2D: a key emerging epigenetic regulator in head and neck diseases and tumors. Life Sci. 2025;369:123523. https:\/\/doi.org\/10.1016\/j.lfs.2025.123523.","journal-title":"Life Sci"},{"issue":"10","key":"354_CR15","doi-asserted-by":"publisher","first-page":"1354","DOI":"10.1038\/s41388-017-0026-x","volume":"37","author":"S Lv","year":"2018","unstructured":"Lv S, Ji L, Chen B, Liu S, Lei C, Liu X, et al. Histone methyltransferase KMT2D sustains prostate carcinogenesis and metastasis via epigenetically activating LIFR and KLF4. Oncogene. 2018;37(10):1354\u201368. https:\/\/doi.org\/10.1038\/s41388-017-0026-x.","journal-title":"Oncogene"},{"issue":"12","key":"354_CR16","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1080\/15592294.2019.1634985","volume":"14","author":"S Lv","year":"2019","unstructured":"Lv S, Wen H, Shan X, Li J, Wu Y, Yu X, et al. Loss of KMT2D induces prostate cancer ROS-mediated DNA damage by suppressing the enhancer activity and DNA binding of antioxidant transcription factor FOXO3. Epigenetics. 2019;14(12):1194\u2013208. https:\/\/doi.org\/10.1080\/15592294.2019.1634985.","journal-title":"Epigenetics"},{"issue":"2","key":"354_CR17","doi-asserted-by":"publisher","first-page":"162","DOI":"10.4103\/aja.aja_36_19","volume":"22","author":"SD Lv","year":"2020","unstructured":"Lv SD, Wang HY, Yu XP, Zhai QL, Wu YB, Wei Q, et al. Integrative molecular characterization of Chinese prostate cancer specimens. Asian J Androl. 2020;22(2):162\u20138. https:\/\/doi.org\/10.4103\/aja.aja_36_19.","journal-title":"Asian J Androl"},{"issue":"12","key":"354_CR18","doi-asserted-by":"publisher","first-page":"6788","DOI":"10.1093\/nar\/gkab489","volume":"49","author":"X Jin","year":"2021","unstructured":"Jin X, Qing S, Li Q, Zhuang H, Shen L, Li J, et al. Prostate cancer-associated SPOP mutations lead to genomic instability through disruption of the SPOP-HIPK2 axis. Nucleic Acids Res. 2021;49(12):6788\u2013803. https:\/\/doi.org\/10.1093\/nar\/gkab489.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"354_CR19","doi-asserted-by":"publisher","first-page":"6662","DOI":"10.1038\/s41467-021-27024-x","volume":"12","author":"C Mukhopadhyay","year":"2021","unstructured":"Mukhopadhyay C, Yang C, Xu L, Liu D, Wang Y, Huang D, et al. G3BP1 inhibits Cul3(SPOP) to amplify AR signaling and promote prostate cancer. Nat Commun. 2021;12(1):6662. https:\/\/doi.org\/10.1038\/s41467-021-27024-x.","journal-title":"Nat Commun"},{"issue":"6","key":"354_CR20","doi-asserted-by":"publisher","first-page":"478","DOI":"10.1091\/mbc.E19-08-0456","volume":"31","author":"R Watanabe","year":"2020","unstructured":"Watanabe R, Maekawa M, Hieda M, Taguchi T, Miura N, Kikugawa T, et al. SPOP is essential for DNA-protein cross-link repair in prostate cancer cells: SPOP-dependent removal of topoisomerase 2A from the topoisomerase 2A-DNA cleavage complex. Mol Biol Cell. 2020;31(6):478\u201390. https:\/\/doi.org\/10.1091\/mbc.E19-08-0456.","journal-title":"Mol Biol Cell"},{"key":"354_CR21","doi-asserted-by":"publisher","unstructured":"Lumahan LEV, Arif M, Whitener AE, Yi P. Regulating androgen receptor function in prostate cancer: exploring the diversity of post-translational modifications. Cells. 2024;13(2). https:\/\/doi.org\/10.3390\/cells13020191.","DOI":"10.3390\/cells13020191"},{"key":"354_CR22","doi-asserted-by":"publisher","DOI":"10.1016\/j.biopha.2022.112882","volume":"149","author":"XM Li","year":"2022","unstructured":"Li XM, Wu HL, Xia QD, Zhou P, Wang SG, Yu X, et al. Novel insights into the SPOP E3 ubiquitin ligase: from the regulation of molecular mechanisms to tumorigenesis. Biomed Pharmacother. 2022;149:112882. https:\/\/doi.org\/10.1016\/j.biopha.2022.112882.","journal-title":"Biomed Pharmacother"},{"key":"354_CR23","doi-asserted-by":"publisher","unstructured":"Rodriguez-Alonso A, Casas-Pais A, Roca-Lema D, Grana B, Romay G, Figueroa A. Regulation of epithelial-mesenchymal plasticity by the E3 ubiquitin-ligases in cancer. Cancers (Basel). 2020;12(11). https:\/\/doi.org\/10.3390\/cancers12113093.","DOI":"10.3390\/cancers12113093"},{"issue":"1","key":"354_CR24","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1038\/s41419-025-08047-4","volume":"16","author":"F Xu","year":"2025","unstructured":"Xu F, Tan C, Tang K, Qiao G, Shao Y, Li X, et al. E3 Ubiquitin ligases Cbl-b and c-Cbl maintain the homeostasis of macrophages by regulating the M-CSF\/M-CSFR signaling axis. Cell Death Dis. 2025;16(1):716. https:\/\/doi.org\/10.1038\/s41419-025-08047-4.","journal-title":"Cell Death Dis"},{"key":"354_CR25","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2021.637040","volume":"11","author":"T Yan","year":"2021","unstructured":"Yan T, Zhou D, Shi Y, Cui D, Jiang J, Han B, et al. Targeting ADT-induced activation of the E3 ubiquitin ligase Siah2 to delay the occurrence of castration-resistant prostate cancer. Front Oncol. 2021;11:637040. https:\/\/doi.org\/10.3389\/fonc.2021.637040.","journal-title":"Front Oncol"},{"key":"354_CR26","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbrc.2025.151460","volume":"752","author":"J Hou","year":"2025","unstructured":"Hou J, Du Y, Cui H. RNF6 promotes cell proliferation of glioblastoma by targeting ubiquitin-mediated degradation of p27. Biochem Biophys Res Commun. 2025;752:151460. https:\/\/doi.org\/10.1016\/j.bbrc.2025.151460.","journal-title":"Biochem Biophys Res Commun"},{"issue":"2","key":"354_CR27","doi-asserted-by":"publisher","first-page":"423","DOI":"10.1038\/s41418-020-00703-w","volume":"28","author":"RB Damgaard","year":"2021","unstructured":"Damgaard RB. The ubiquitin system: from cell signalling to disease biology and new therapeutic opportunities. Cell Death Differ. 2021;28(2):423\u20136. https:\/\/doi.org\/10.1038\/s41418-020-00703-w.","journal-title":"Cell Death Differ"},{"issue":"9","key":"354_CR28","doi-asserted-by":"publisher","DOI":"10.1016\/j.jbc.2022.102314","volume":"298","author":"H Zhuang","year":"2022","unstructured":"Zhuang H, Ren Y, Mao C, Zhong Y, Zhang Z, Cao B, et al. Induction of zinc finger protein RNF6 auto-ubiquitination for the treatment of myeloma and chronic myeloid leukemia. J Biol Chem. 2022;298(9):102314. https:\/\/doi.org\/10.1016\/j.jbc.2022.102314.","journal-title":"J Biol Chem"},{"issue":"1","key":"354_CR29","doi-asserted-by":"publisher","DOI":"10.1080\/23723556.2022.2030171","volume":"9","author":"C Mukhopadhyay","year":"2022","unstructured":"Mukhopadhyay C, Zhou P. G3BP1 modulates SPOP to promote prostate tumorigenesis. Mol Cell Oncol. 2022;9(1):2030171. https:\/\/doi.org\/10.1080\/23723556.2022.2030171.","journal-title":"Mol Cell Oncol"},{"issue":"19","key":"354_CR30","doi-asserted-by":"publisher","first-page":"10929","DOI":"10.1093\/nar\/gkac861","volume":"50","author":"J Wang","year":"2022","unstructured":"Wang J, Park KS, Yu X, Gong W, Earp HS, Wang GG, et al. A cryptic transactivation domain of EZH2 binds AR and AR\u2019s splice variant, promoting oncogene activation and tumorous transformation. Nucleic Acids Res. 2022;50(19):10929\u201346. https:\/\/doi.org\/10.1093\/nar\/gkac861.","journal-title":"Nucleic Acids Res"},{"key":"354_CR31","doi-asserted-by":"publisher","unstructured":"Kanayama M, Lu C, Luo J, Antonarakis ES. AR splicing variants and resistance to AR targeting agents. Cancers (Basel). 2021;13(11). https:\/\/doi.org\/10.3390\/cancers13112563.","DOI":"10.3390\/cancers13112563"},{"issue":"1","key":"354_CR32","doi-asserted-by":"publisher","first-page":"471","DOI":"10.1038\/s41420-022-01257-1","volume":"8","author":"M Luo","year":"2022","unstructured":"Luo M, Zhang Y, Xu Z, Wu C, Ye Y, Liu R, et al. Tautomycin and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Cell Death Discov. 2022;8(1):471. https:\/\/doi.org\/10.1038\/s41420-022-01257-1.","journal-title":"Cell Death Discov"},{"issue":"15","key":"354_CR33","doi-asserted-by":"publisher","first-page":"1446","DOI":"10.1002\/pros.24607","volume":"83","author":"Y Zhang","year":"2023","unstructured":"Zhang Y, Liao Y, Luo M, Ye Y, Xu Z, Hou W, et al. IU1 and enzalutamide combination yields synergistic effects on castration-resistant prostate cancer. Prostate. 2023;83(15):1446\u201357. https:\/\/doi.org\/10.1002\/pros.24607.","journal-title":"Prostate"},{"issue":"6","key":"354_CR34","doi-asserted-by":"publisher","first-page":"1199","DOI":"10.1016\/j.euo.2024.04.011","volume":"7","author":"M Pedrani","year":"2024","unstructured":"Pedrani M, Salfi G, Merler S, Testi I, Cani M, Turco F, et al. Prognostic and predictive role of SPOP mutations in prostate cancer: a systematic review and meta-analysis. Eur Urol Oncol. 2024;7(6):1199\u2013215. https:\/\/doi.org\/10.1016\/j.euo.2024.04.011.","journal-title":"Eur Urol Oncol"},{"issue":"4","key":"354_CR35","doi-asserted-by":"publisher","first-page":"402","DOI":"10.1006\/meth.2001.1262","volume":"25","author":"KJ Livak","year":"2001","unstructured":"Livak KJ, Schmittgen TD. Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods. 2001;25(4):402\u20138. https:\/\/doi.org\/10.1006\/meth.2001.1262.","journal-title":"Methods"}],"container-title":["Molecular Biomedicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s43556-025-00354-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s43556-025-00354-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:06:04Z","timestamp":1763424364000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s43556-025-00354-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,17]]},"references-count":35,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["354"],"URL":"https:\/\/doi.org\/10.1186\/s43556-025-00354-8","relation":{},"ISSN":["2662-8651"],"issn-type":[{"value":"2662-8651","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,17]]},"assertion":[{"value":"12 October 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 October 2025","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 November 2025","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2025","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No human tissue was used for this research, and no ethical permission was applicable. For animal experiments, the animal use protocol was approved by the Animal Care and Use Committee of Ganzhou People\u2019s Hospital (Approval No.: TY-DKY2023-020\u201301).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors have no relevant financial or non-financial interests to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"112"}}